TOKYO - Japanese pharmaceutical firm Eisai Co. said Monday it and U.S. firm Biogen Inc. applied with the health ministry for approval of an Alzheimer's drug that could become the first available in Japan that both treats the disease's cause and slows symptom progression.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
